These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
355 related articles for article (PubMed ID: 32956895)
1. Current pharmacological intervention and development of targeting IVIG resistance in Kawasaki disease. Zhang RL; Lo HH; Lei C; Ip N; Chen J; Law BY Curr Opin Pharmacol; 2020 Oct; 54():72-81. PubMed ID: 32956895 [TBL] [Abstract][Full Text] [Related]
2. Adjuvant herbal therapy for targeting susceptibility genes to Kawasaki disease: An overview of epidemiology, pathogenesis, diagnosis and pharmacological treatment of Kawasaki disease. Tang B; Lo HH; Lei C; U KI; Hsiao WW; Guo X; Bai J; Wong VK; Law BY Phytomedicine; 2020 Apr; 70():153208. PubMed ID: 32283413 [TBL] [Abstract][Full Text] [Related]
3. Phenotype, Susceptibility, Autoimmunity, and Immunotherapy Between Kawasaki Disease and Coronavirus Disease-19 Associated Multisystem Inflammatory Syndrome in Children. Chen MR; Kuo HC; Lee YJ; Chi H; Li SC; Lee HC; Yang KD Front Immunol; 2021; 12():632890. PubMed ID: 33732254 [TBL] [Abstract][Full Text] [Related]
4. A low-frequency IL4R locus variant in Japanese patients with intravenous immunoglobulin therapy-unresponsive Kawasaki disease. Amano Y; Akazawa Y; Yasuda J; Yoshino K; Kojima K; Kobayashi N; Matsuzaki S; Nagasaki M; Kawai Y; Minegishi N; Ishida N; Motoki N; Hachiya A; Nakazawa Y; Yamamoto M; Koike K; Takeshita T Pediatr Rheumatol Online J; 2019 Jul; 17(1):34. PubMed ID: 31269967 [TBL] [Abstract][Full Text] [Related]
5. Exploring the relationship between pyroptosis, infiltrating immune cells and Kawasaki disease with resistance to intravenous immunoglobulin (IVIG) via bioinformatic analysis. Xie Y; Han B Immunobiology; 2022 Sep; 227(5):152261. PubMed ID: 36029669 [TBL] [Abstract][Full Text] [Related]
7. Kawasaki disease in Turkish children: a single center experience with emphasis on intravenous immunoglobulin resistance and giant coronary aneurysms. Yılmazer MM; Özdemir R; Meşe T; Küçük M; Öner T; Devrim İ; Bayram N; Güven B; Tavlı V Turk J Pediatr; 2019; 61(5):648-656. PubMed ID: 32104995 [TBL] [Abstract][Full Text] [Related]
8. Transcript abundance patterns in Kawasaki disease patients with intravenous immunoglobulin resistance. Fury W; Tremoulet AH; Watson VE; Best BM; Shimizu C; Hamilton J; Kanegaye JT; Wei Y; Kao C; Mellis S; Lin C; Burns JC Hum Immunol; 2010 Sep; 71(9):865-73. PubMed ID: 20600450 [TBL] [Abstract][Full Text] [Related]
9. Association between P2RY12 Gene Polymorphisms and IVIG Resistance in Kawasaki Patients. Wang Z; Xu Y; Zhou H; Wang Y; Li W; Lu Z; Jiang Z; Gu X; Zheng H; Zeng L; Huang P; Zhang L; Gu X Cardiovasc Ther; 2020; 2020():3568608. PubMed ID: 32256707 [TBL] [Abstract][Full Text] [Related]
10. Association of CCR2-CCR5 haplotypes and CCL3L1 copy number with Kawasaki Disease, coronary artery lesions, and IVIG responses in Japanese children. Mamtani M; Matsubara T; Shimizu C; Furukawa S; Akagi T; Onouchi Y; Hata A; Fujino A; He W; Ahuja SK; Burns JC PLoS One; 2010 Jul; 5(7):e11458. PubMed ID: 20628649 [TBL] [Abstract][Full Text] [Related]
11. Risk factors of immunoglobulin resistance and coronary complications in children with Kawasaki disease. Berdej-Szczot E; Małecka-Tendera E; Gawlik T; Firek-Pędras M; Szydłowski L; Gawlik A Kardiol Pol; 2017; 75(3):261-266. PubMed ID: 27995598 [TBL] [Abstract][Full Text] [Related]
12. Epidemiologic study of Kawasaki disease and cases resistant to IVIG therapy in Thailand. Durongpisitkul K; Sangtawesin C; Khongphatthanayopthin A; Panamonta M; Sopontammarak S; Sittiwangkul R; Pongpanich B Asian Pac J Allergy Immunol; 2006 Mar; 24(1):27-32. PubMed ID: 16913186 [TBL] [Abstract][Full Text] [Related]
13. Variations in the number of CCL3L1 gene copies and Kawasaki disease in Korean children. Kim HE; Kim JJ; Han MK; Lee KY; Song MS; Lee HD; Kim DS; Yu JJ; Park IS; Yun SW; Hong YM; Jang GY; Lee JK; Pediatr Cardiol; 2012 Dec; 33(8):1259-63. PubMed ID: 22450355 [TBL] [Abstract][Full Text] [Related]
14. Association of Genetic Polymorphisms in Kawasaki Disease with the Response to Intravenous Immunoglobulin Therapy. Sapountzi E; Fidani L; Giannopoulos A; Galli-Tsinopoulou A Pediatr Cardiol; 2023 Jan; 44(1):1-12. PubMed ID: 35908117 [TBL] [Abstract][Full Text] [Related]
15. A Retrospective Cohort Study of Intravenous Immunoglobulin Therapy in the Acute Phase of Kawasaki Disease: The Earlier, the Better? Li W; He X; Zhang L; Wang Z; Wang Y; Lin H; Yuan J; Xie X; Qin Y; Huang P Cardiovasc Ther; 2021; 2021():6660407. PubMed ID: 34239607 [TBL] [Abstract][Full Text] [Related]
17. Kawasaki disease: a comprehensive review of treatment options. Patel RM; Shulman ST J Clin Pharm Ther; 2015 Dec; 40(6):620-5. PubMed ID: 26547265 [TBL] [Abstract][Full Text] [Related]
18. Association of the IL16 Asn1147Lys polymorphism with intravenous immunoglobulin resistance in Kawasaki disease. Kim HJ; Kim JJ; Yun SW; Yu JJ; Yoon KL; Lee KY; Kil HR; Kim GB; Han MK; Song MS; Lee HD; Ha KS; Hong YM; Jang GY; Lee JK; J Hum Genet; 2020 Apr; 65(4):421-426. PubMed ID: 31965063 [TBL] [Abstract][Full Text] [Related]
20. Predictors for Intravenous Immunoglobulin Resistance in Patients with Kawasaki Disease. Li W; Zhang L; Wang Z; He X; Lin H; Wang Y; Yuan J; Xie X; Zhang X; Qin Y; Huang P Int J Clin Pract; 2022; 2022():2726686. PubMed ID: 35989868 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]